MA38456A1 - Utilisation de pidotimode pour traiter le syndrome du côlon irritable - Google Patents

Utilisation de pidotimode pour traiter le syndrome du côlon irritable

Info

Publication number
MA38456A1
MA38456A1 MA38456A MA38456A MA38456A1 MA 38456 A1 MA38456 A1 MA 38456A1 MA 38456 A MA38456 A MA 38456A MA 38456 A MA38456 A MA 38456A MA 38456 A1 MA38456 A1 MA 38456A1
Authority
MA
Morocco
Prior art keywords
pidotimode
bowel syndrome
irritable bowel
treat irritable
acceptable salt
Prior art date
Application number
MA38456A
Other languages
English (en)
Other versions
MA38456B1 (fr
Inventor
Federico Mailland
Maurizio Caserini
Francesco Scarci
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA38456A1 publication Critical patent/MA38456A1/fr
Publication of MA38456B1 publication Critical patent/MA38456B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur l'utilisation du pidotimode, ou d'un sel physiologiquement acceptable de celui-ci, pour traiter le syndrome du côlon irritable. Le traitement décrit dans l'invention consiste à administrer par voie orale ou rectale du pidotimode ou un sel pharmaceutiquement acceptable de celui-ci.
MA38456A 2013-04-05 2013-04-05 Utilisation de pidotimode pour traiter le syndrome du côlon irritable MA38456B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/057205 WO2014161594A1 (fr) 2013-04-05 2013-04-05 Utilisation de pidotimode pour traiter le syndrome du côlon irritable

Publications (2)

Publication Number Publication Date
MA38456A1 true MA38456A1 (fr) 2017-11-30
MA38456B1 MA38456B1 (fr) 2018-04-30

Family

ID=48236865

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38456A MA38456B1 (fr) 2013-04-05 2013-04-05 Utilisation de pidotimode pour traiter le syndrome du côlon irritable

Country Status (21)

Country Link
US (1) US9446027B2 (fr)
EP (1) EP2981290A1 (fr)
JP (1) JP6049938B2 (fr)
KR (1) KR20150140649A (fr)
CN (1) CN105073137A (fr)
AR (1) AR095961A1 (fr)
AU (1) AU2013385169A1 (fr)
BR (1) BR112015025291A2 (fr)
CA (1) CA2901284A1 (fr)
EA (1) EA201591929A1 (fr)
EC (1) ECSP15041985A (fr)
HK (1) HK1216151A1 (fr)
IL (1) IL241785A0 (fr)
MA (1) MA38456B1 (fr)
MX (1) MX2015014060A (fr)
NI (1) NI201500146A (fr)
PH (1) PH12015502304A1 (fr)
SG (1) SG11201506480VA (fr)
TN (1) TN2015000431A1 (fr)
UA (1) UA113468C2 (fr)
WO (1) WO2014161594A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231723B (it) 1989-08-11 1991-12-21 Poli Ind Chimica Spa Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6946465B2 (en) 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
CN101011362A (zh) * 2007-02-01 2007-08-08 山东益康药业有限公司 匹多莫德分散片及其制备方法和应用
ITTO20070480A1 (it) 2007-07-02 2009-01-03 Marvecspharma Service S R L Impiego di pidotimod, somministrato per via intranasale per potenziare la risposta immunitaria umorale e cellulare antigene-specifica
US20090142769A1 (en) 2007-11-29 2009-06-04 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for determining anti-TNF therapeutic response
CN101623499A (zh) * 2008-07-07 2010-01-13 杨喜鸿 抗生素和匹多莫德的药物组合物及其制备方法和药物应用

Also Published As

Publication number Publication date
BR112015025291A2 (pt) 2017-07-18
MX2015014060A (es) 2016-04-07
TN2015000431A1 (en) 2017-01-03
AR095961A1 (es) 2015-11-25
PH12015502304A1 (en) 2016-02-15
CN105073137A (zh) 2015-11-18
AU2013385169A1 (en) 2015-09-03
CA2901284A1 (fr) 2014-10-09
NI201500146A (es) 2016-01-06
ECSP15041985A (es) 2015-11-30
US9446027B2 (en) 2016-09-20
IL241785A0 (en) 2015-11-30
US20160058740A1 (en) 2016-03-03
JP2016515590A (ja) 2016-05-30
JP6049938B2 (ja) 2016-12-21
WO2014161594A1 (fr) 2014-10-09
EA201591929A1 (ru) 2016-02-29
HK1216151A1 (zh) 2016-10-21
SG11201506480VA (en) 2015-10-29
MA38456B1 (fr) 2018-04-30
KR20150140649A (ko) 2015-12-16
UA113468C2 (uk) 2017-01-25
EP2981290A1 (fr) 2016-02-10

Similar Documents

Publication Publication Date Title
MA55021A (fr) 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
FR3004920B1 (fr) Dispositif d'osteotomie, en particulier pour la realisation du scarf extreme dans le traitement de l'hallux valgus severe.
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA52575A (fr) Pansement pour le traitement de la peau endommagée
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
MA47719A (fr) Esketamine pour le traitement de la dépression
FR2957246B1 (fr) Dispositif orthopedique pour le traitement de l'hallux valgus par reaxation de l'hallux valgus par effet mecanique
FR23C1002I2 (fr) 2,4,6-trifluoro-n-ý6-(l-méthyl-pipéridin-4- carbonyl)-pyridin-2-yl]-benzamide destiné au traitement de la migraine par la voie orale ou intraveineuse
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
FR3045392B1 (fr) Dispositif pour le traitement d'un sujet par combinaison notamment de la lithotherapie, la chromotherapie, la luminotherapie et la musicotherapie
MA38456A1 (fr) Utilisation de pidotimode pour traiter le syndrome du côlon irritable
MA38155B1 (fr) Utilisation du pidotimod pour traiter le psoriasis
FR3014693B1 (fr) Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
MA38156A1 (fr) Utilisation du pidotimod pour traiter la dermatite atopique
MA38455A1 (fr) Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA39833B1 (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide
MA53933A (fr) Poly-immunothérapie pour le traitement du cancer du sein triple-négatif